Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Technetium[99mTc] isonitrile glucosamine (99mTc-CNDG7) SPECT/CT for regional lymph node metastasis in non-small cell lung cancer
CTR20262746Phase 2Active
- Sponsor
- Shihong Pharmaceutical
- Start
- Aug 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of technetium [99mtc] isonitrile glucosamine in non-small cell lung cancer (NSCLC), sponsored by Shihong Pharmaceutical. Started Aug 2026; status: active.
02
Drugs
technetium [99mtc] isonitrile glucosamine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20262746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262746.